# Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

> **NCT02639650** · PHASE3 · UNKNOWN · sponsor: **Weiguo Lv** · enrollment: 214 (estimated)

## Conditions studied

- Gestational Trophoblastic Neoplasms

## Interventions

- **DRUG:** Etoposide
- **DRUG:** actinomycin D
- **DRUG:** methotrexate
- **DRUG:** vincristine
- **DRUG:** cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02639650
- **Lead sponsor:** Weiguo Lv
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2022-06-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02639650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02639650, "Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02639650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*